Abstract
Integrins are a large family of transmembrane heterodimeric proteins that constitute the main receptors for extracellular matrix components. Integrins were initially thought to be primarily involved in the maintenance of cell adhesion and tissue integrity. However, it is now appreciated that integrins play important roles in many other biological processes such as cell survival, proliferation, differentiation, migration, cell shape and polarity. Lung cells express numerous combinations and permutations of integrin heterodimers. The complexity and diversity of different integrin heterodimers being implicated in different lung diseases present a major challenge for drug development. Here we provide a comprehensive overview of the current knowledge of integrins from studies in cell culture to integrin knockout mouse models and provide an update of results from clinical trials for which integrins are therapeutic targets with a focus on respiratory diseases (asthma, emphysema, pneumonia, lung cancer, pulmonary fibrosis and sarcoidosis).
Keywords: Asthma, emphysema, integrins, lung cancer, lung disease, pulmonary fibrosis, sarcoidosis.
Current Molecular Medicine
Title:Integrins as Therapeutic Targets for Respiratory Diseases
Volume: 15 Issue: 8
Author(s): C. M. Teoh, S. S.L. Tan and T. Tran
Affiliation:
Keywords: Asthma, emphysema, integrins, lung cancer, lung disease, pulmonary fibrosis, sarcoidosis.
Abstract: Integrins are a large family of transmembrane heterodimeric proteins that constitute the main receptors for extracellular matrix components. Integrins were initially thought to be primarily involved in the maintenance of cell adhesion and tissue integrity. However, it is now appreciated that integrins play important roles in many other biological processes such as cell survival, proliferation, differentiation, migration, cell shape and polarity. Lung cells express numerous combinations and permutations of integrin heterodimers. The complexity and diversity of different integrin heterodimers being implicated in different lung diseases present a major challenge for drug development. Here we provide a comprehensive overview of the current knowledge of integrins from studies in cell culture to integrin knockout mouse models and provide an update of results from clinical trials for which integrins are therapeutic targets with a focus on respiratory diseases (asthma, emphysema, pneumonia, lung cancer, pulmonary fibrosis and sarcoidosis).
Export Options
About this article
Cite this article as:
Teoh M. C., Tan S.L. S. and Tran T., Integrins as Therapeutic Targets for Respiratory Diseases, Current Molecular Medicine 2015; 15 (8) . https://dx.doi.org/10.2174/1566524015666150921105339
DOI https://dx.doi.org/10.2174/1566524015666150921105339 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Docking Analysis of Flavonoid Compounds with Matrix Metalloproteinase- 8 for the Identification of Potential Effective Inhibitors
Letters in Drug Design & Discovery Synthesis of Aza-BODIPY Boron Difluoride PDT Agents to Promote Apoptosis in HeLa Cells
Letters in Organic Chemistry Novel Derivatives of Benfluron and Dimefluron Synthesis and Anticancer activity
Letters in Drug Design & Discovery TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Novel 1, 2, 3-Triazole-Linked Norcantharidin Analogues: Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines
Letters in Drug Design & Discovery Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Anti-cancer Potential of Phyto-alkaloids: A Prospective Review
Current Cancer Therapy Reviews Investigations of Malignant Mesothelioma
Current Respiratory Medicine Reviews Synthesis, Biological Evaluation and Molecular Docking Studies Against EGFR Tyrosine Kinase of 3,5-bis(substituted benzylidene)-1- ethylpiperidin-4-one Analogues
Letters in Organic Chemistry Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry Technological Advances in Preclinical Drug Evaluation: The Role of -Omics Methods
Current Medicinal Chemistry Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Efficient Purification of rhG-CSF and its PEGylated Forms and Evaluation for In Vitro Activities
Protein & Peptide Letters Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets